Supernus Pharmaceuticals, Inc. SUPN
42.66
(0.63)
(1.46%)
as of 25 Sep
- Market cap
- $2.5B
- P/E
- 0.0×
Follow SUPN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (10.49%) | (2.75%) | (3.68%) | (1.86%) |
+8 more TTM periods Free account |
|
| (7.82%) | (2.04%) | (2.73%) | (1.38%) | ||
ROIC |
(12.37%) | (5.45%) | (5.17%) | (3.00%) | |
Return on Tangible Assets |
(28.44%) | (7.89%) | (12.18%) | (6.98%) | |
Average Days of Receivables |
93.03 | 85.60 | 95.34 | 91.72 | |
Free Cash Flow per Share |
0.32 | 1.44 | 0.81 | 1.25 | |
Free Cash Flow |
18.33 | 83.26 | 45.99 | 70.75 | |
Capital Expenditures |
(1.58) | — | (1.34) | (1.12) | |
Piotroski F-Score |
3.00 | 4.00 | 4.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
1.42% | 5.70% | 3.45% | 5.40% | |
Accounts Receivable Turnover |
4.71 | 4.74 | 4.36 | 4.30 | |
Accounts Payable Turnover |
1.06 | 0.92 | 0.81 | 0.84 | |
Inventory Turnover |
1.55 | 1.20 | 1.09 | 1.08 | |
Average Days of Payables |
399.74 | 449.62 | 527.71 | 510.52 | |
Days of Inventory on Hand |
309.32 | 386.64 | 403.30 | 373.21 | |
Tax Rate |
(0.11) | (0.41) | (0.21) | (0.08) | |
Research and Development Expense of Revenue |
15.18% | 15.29% | 14.78% | 15.71% | |
Selling, General and Administrative Expense of Revenue |
67.54% | 67.04% | 67.54% | 64.94% | |
Share Based Compensation of Revenue |
4.17% | 4.31% | 4.60% | 4.55% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.18) | (2.87) | (1.23) | (3.76) | |
Depreciation/Fixed assets |
9.88 | 9.63 | 8.55 | 7.78 | |
Capex/Depreciation |
(0.02) | 0.00 | (0.01) | (0.01) | |
Revenue per Share |
14.30 | 13.48 | 12.74 | 12.05 | |
Operating CF per Share |
0.34 | 1.44 | 0.84 | 1.27 | |
Capex per Share |
(0.03) | 0.00 | (0.02) | (0.02) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(13.23%) | (3.74%) | (5.36%) | (2.80%) |
Columns are period end dates